“…In the Polish part of the EUROASPIRE IV study, over 80% of patients were taking lipid-lowering medication (36% statins at high dose). 22,23 Nevertheless, overall, only about 25% were at treatment target of LDL-C of less than 1.8 mmol/l, which is, in any case, a 2-fold difference from the very high-risk group in the general population. 22,23 The use of moderate-intensity and high-intensity statin therapy in WOBASZ II seems to be more frequent than that found in the 3ST-POL study of nearly 50 000 ambulatory patients in Poland before 2010, in which almost 71% of patients received the daily statin dose of less than 20 mg.…”